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Introduction
In Korea, ovarian cancer is the tenth most prevalent cancer 
and the eighth leading cause of cancer-related deaths in 
women [1]. In 2015, 9.6 new cases of ovarian cancer and 7.2 
cancer-related deaths per 100,000 women were reported. 
Epithelial ovarian carcinoma (EOC), which accounts for more 
than 85% of all ovarian cancers, is more aggressive than 
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non-EOC, and it is responsible for 90% of ovarian cancer-
related deaths. The four most common subtypes of EOC are 
serous (80‒85%), clear cell (5%), endometrioid (10%), and 
mucinous (3%) ovarian neoplasm, as categorized by their 
traditional histomorphologic features [2,3]. A 2-tier grading 
system for serous ovarian carcinoma subdivided these tumors 
into low-grade serous carcinoma (LGSC, type I) and high-
grade serous carcinoma (HGSC, type II) [4], and HGSC is 20 
times more likely than LGSC to cause death [5]. As effective 
screening methods for early detection of EOC are still un-
known, more than 70% of ovarian cancers are diagnosed in 
advanced stages, with poor survival outcomes [6].
The risk factors for ovarian cancer include age, menopausal 
status, parity, and family history. Germline mutation in BRCA1 
or BRCA2 is associated with autosomal-dominant hereditary 
breast and ovarian cancer (HBOC) and hereditary non-polypo-
sis colorectal cancer (HNPCC), and it carries an approximately 
40% lifetime risk of ovarian cancer [7,8]. Germline mutation 
in BRCA1 or BRCA2 is found in 12‒15% of cases of EOC, and 
the carcinomas that develop in patients with these mutations 
are commonly high-grade serous in type [9-11]. The lifetime 
risks of EOC (mainly endometrioid and clear cell types) owing 
to mutations in MSH2, MLH1, and MSH6, which are known 
as mismatch repair genes associated with HNPCC, are approx-
imately 10%, 8%, and 7%, respectively [12]. Although HBOC 
and HNPCC are the most well-known conditions that predis-
pose to EOC, mutations in BRIP1, RAD51D, and RAD51C are 
associated with a 10‒15% lifetime risk of cancer [13-15].
To prevent EOC in women at a high risk for the disease, 
removal of the ovaries and fallopian tubes, known as risk-
reducing salpingo-oophorectomy (RRSO), is commonly rec-
ommended. The recommended age range for performing 
RRSO in women with BRCA1 and BRCA2 germline mutations 
is 35–40 years and 40–45 years, respectively, as per the Na-
tional Comprehensive Cancer Network (NCCN) guideline [16]. 
In 2016, the Korean Society of Obstetrics and Gynecology 
(KSGO) recommended that women with a BRCA germline 
mutation should be counseled about RRSO at 35–40 years of 
age on an individual basis [17]. Meanwhile, as RRSO results 
in surgical menopause, which can affect the cardiovascu-
lar system, osteoporotic health, and quality of life [18,19], 
prophylactic salpingectomy and delayed oophorectomy 
(PSDO) is now under clinical trials as an alternative of RRSO 
in premenopausal women at a high risk for ovarian cancer 
(NCT02321228, NCT01907789). Contrary to RRSO in high-
risk women, the surgical strategy to prevent EOC in women 
at average risk* is controversial.
*Women at an average risk for EOC (those who meet all criteria)
A.  Age 18 years and older
B.  No known family history of ovarian, breast, or colon cancer
C.  No known germline mutation in BRCA1, BRCA2, mis-
match repair genes (MLH1, MSH2, MSH6, PMS2), EP-
CAM, BRIP1, RAD51C, and RAD51D, which increases the 
risk of ovarian/fallopian/peritoneal cancer
Fig. 1. Sectioning and extensive examination the fimbriated end protocol. (A) A fallopian tube demonstrating longitudinal sectioning of 
the fimbria and extensive cross-sectioning of the remainder of the tube at 2–3-mm intervals and (B) preparing cross-sections of the fal-
lopian tube.
A  B
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Carcinogenesis in the ovarian 
epithelium — a tubal paradigm
LGSC has been hypothesized to arise from a serous cystad-
enoma or adenofibroma, and is characterized by mutations 
in the KRAS, BRAF, or ERBB2 genes, in which approximately 
two-thirds of the tumors harbor a mutation [20-22]. Unlike 
LGSC, mutations in KRAS, BRAF, or ERBB2 rarely occur in 
HGSC. In contrast, TP53 mutation frequently occurs in more 
than 80% cases of HGSC [23,24]. TP53 mutations result in 
an increased nonfunctional p53; this is referred to as a “p53 
signature,” which is commonly identified in HGSC [22]. 
The increasing RRSO in the high-risk women and improved 
pathologic assessments would have enabled pathologists to 
detect more p53 signatures derived from TP53 mutation ad-
jacent to serous tubal intraepithelial carcinoma (STIC) lesions 
[25]. Sectioning and Extensively Examining the Fimbriated 
End (SEE-FIM) protocol involves a meticulous examination of 
the fallopian tubes of high-risk women who undergo RRSO; 
it entails amputation of each fimbria at the infundibulum, 
longitudinal sectioning of the fimbria, and extensive cross-
sectioning of the remainder of the tube at 2–3-mm intervals 
[26] (Fig. 1). STIC is now generally accepted as the earliest 
morphologically recognizable form of HGSC.
STIC and invasive tubal carcinoma were detected more 
frequently in patients who had a genetic predisposition to 
EOC; however, they were also detected in non-mutation 
carriers with HGSC, with a prevalence of 48‒75% [27-30]. 
According to the results of a recently published Gynecologic 
Oncology Group-0199 trial, occult, invasive, or serous tubal 
intraepithelial lesions were identified in 25 out of 966 high-
risk women who underwent RRSO: 4.6%, 3.5%, and 0.5% 
of occult lesions were detected in women who had BRCA1 
germline mutation, BRCA2 germline mutation, and were 
high-risk non-carriers, respectively [31]. More than 90% of 
these precancerous lesions were localized to the fimbrial end 
in both women who had BRCA germline mutations and in 
those who did not have the mutations [26,28,29]. The aver-
age time from STIC to HGSC was estimated as 6.5 (range, 
1.4–10.7) years, and the time between the initiation of the 
HGSC and the development of peritoneal carcinomatosis 
appears to be very short in women with metastatic STIC le-
sions [32].
Although increasing evidences for the pathological as-
sociation between STIC and HGSC are still observed, it is 
noteworthy that all HGSCs do not have tubal precancerous 
lesions. The possibility of non-tubal origin and an alternative 
carcinogenetic process persists, and further studies on ovar-
ian tissue factors including hormonal milieu or ovulation are 
warranted.
Preventive effect of salpingectomy on 
ovarian/fallopian/peritoneal cancers
It is known that not only sterilization but also tubal ligation 
confers a decreased risk of EOC. Several meta-analyses have 
demonstrated an approximately 26–34% decrease in the risk 
of EOC in women undergoing tubal ligation [33-37]. This 
effect is more pronounced in endometrioid and clear cell tu-
mors than in serous tumors. It has been understood that the 
location of the ligation near the utero-tubal junction prevents 
the retrograde transport and ovarian seeding of endometri-
otic cells, which has been consistently linked to endometrioid 
and clear cell tumors. On the contrary, the risk of serous tu-
mors is considerably reduced by excisional tubal sterilization 
rather than non-excisional tubal sterilization. Several nation-
wide studies have reported that salpingectomy decreases the 
risk of ovarian cancer by 42–77% [38-40]. Lessard-Anderson 
et al. [38] suggested that compared to other sterilization 
methods, excisional sterilization may more effectively reduce 
the risk of ovarian cancer. They compared the number of 
tubal sterilization cases between 194 women with serous 
ovarian/peritoneal cancer and matched them with 388 con-
trols. The rate of excisional tubal sterilization was lower in 
the cancer group than in the controls (2.6% vs. 6.4%), and 
the adjusted risk of serous ovarian/peritoneal cancer was de-
creased by 64% after excisional tubal sterilization compared 
to the risk after non-excisional tubal sterilization or no steril-
ization (odds ratios [ORs], 0.36; 95% confidence interval [CI], 
0.13–1.02). Similarly, Madsen et al. conducted a case-control 
study based on a nationwide registry (case group of ovarian 
cancer, n=13,241) [39]. They reported that tubal steriliza-
tion and bilateral salpingectomy reduce the risk of EOC by 
13% and 42%, respectively (OR, 0.87; 95% CI, 0.78–0.98 
and OR, 0.58; 95% CI, 0.36–0.95, respectively). Falconer et 
al. also revealed that salpingectomy for benign indications 
is associated with a reduced risk of ovarian cancer, in a na-
tional population-based cohort study [40]. Women who had 
previously undergone a salpingectomy (n=251,465) showed 
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a significantly lower risk for ovarian cancer than that of 
women who had not undergone a salpingectomy (OR, 0.65; 
95% CI, 0.52–0.81). In particular, bilateral salpingectomy 
was associated with a 50% decreased risk of ovarian cancer, 
compared to unilateral salpingectomy (OR, 0.35; 95% CI, 
0.17–0.73 and OR, 0.71; 95% CI, 0.56–0.91, respectively). 
Although the retrospective studies cannot confirm the causal 
relationship for prevention of ovarian cancer, these nation-
wide population-based results are quite noteworthy. In 2016, 
Yoon et al. [41] reported the results of a meta-analysis based 
on these nationwide population-based studies. The risks of 
ovarian cancer were compared between 3,509 women who 
underwent bilateral salpingectomy and 5,655,702 women 
who did not undergo salpingectomy. Bilateral salpingectomy 
was revealed to reduce the risk of ovarian cancer by 49% (OR, 
0.51; 95% CI, 0.35–0.75; I2=0%).
Other position statements on prophylactic 
salpingectomy and its current state
Several professional gynecologic boards have carefully stated 
a favorable position of prophylactic salpingectomy at the 
time of benign gynecologic surgery or other intraperitoneal 
surgery [42-47] (Table 1). In 2013, the Society of Gyneco-
logic Oncology (SGO) stated the following: “For women at 
average risk of ovarian cancer, risk-reducing salpingectomy 
should also be discussed and considered with patients at the 
time of abdominal or pelvic surgery, hysterectomy or in lieu 
of tubal ligation” [43,44]. Subsequently, the Royal College 
of Obstetricians and Gynecologists (RCOG) and the Ameri-
can College of Obstetricians and Gynecologists also stated, 
in 2014 and 2015, respectively, that bilateral salpingectomy 
should be considered at the time of benign gynecologic sur-
gery or other intraperitoneal surgery in women who have 
completed their families [45,46]. These societies supported 
that bilateral salpingectomy has a potential benefit to pre-
vent ovarian cancer, with minimal procedure-related compli-
cations.
Prophylactic salpingectomy is increasingly performed in 
many countries. In the United States, the rate of performing 
prophylactic salpingectomy with hysterectomy increased by 
371% in 5 years (2008–2013) [48]. However, it was revealed 
that 45.5% of American physicians do not routinely perform 
prophylactic salpingectomy in real practice, and 69.4% of 
them said that they actually do not believe that salpingec-
tomy exerts a preventive effect on ovarian cancer, in a survey 
study [49]. Although there is a wide discrepancy in the re-
sponses of physicians from European countries, 32.7–80% 
of physicians routinely perform prophylactic salpingectomy 
during benign gynecologic surgery [50-52]. In Austria, 70% 
(269/382) of the respondents stated that they would offer 
or discuss prophylactic salpingectomy in average-risk women 
undergoing gynecological surgery for benign indications, and 
that salpingectomy was the preferred method for surgical 
sterilization at the time of cesarean delivery [51,53]. Prophy-
Table 1. Other position statements on prophylactic salpingectomy by professional gynecologic boards
Year Associations or experts Recommendations
2011 Royal Australian and New Zealand college 
of obstetricians and gynecologists [42]
Doctors should discuss the risks and benefits of bilateral salpingectomy with patients 
undergoing hysterectomy for benign disease.
2013 Society of Gynecologic Oncology [43,44] For women at average risk of ovarian cancer, risk-reducing salpingectomy should 
also be discussed and considered at the time of abdominal or pelvic surgery, 
hysterectomy or in lieu of tubal ligation.
2014 Royal College of Obstetricians and 
Gynecologists [45]
Women who are not at high risk for BRCA mutation and those who have completed 
their families should be carefully considered for prophylactic removal of the 
fallopian tubes with conservation of ovaries at the time of gynecological or other 
intraperitoneal surgery.
2015 American college of obstetricians and 
gynecologists [46]
Women at population-level risk of ovarian cancer who are undergoing ovary-sparing 
hysterectomy for benign indications should be offered bilateral salpingectomy to 
reduce their risk of ovarian cancer.
2015 Commission Ovary of the 
Arbeitsgemeinschaft Gynäkologische 
Onkologie [47]
During preoperative counseling prior to hysterectomy, all patients should be 
informed about the potential beneficial impact of opportunistic salpingectomy and 
the associated risks.
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lactic salpingectomy at the time of hysterectomy for benign 
disease was applied to women in 70–80% of institutions 
accredited by an academic society and in 50–65% of institu-
tions not accredited by an academic society in Japan [54]. In 
China, the rate of bilateral salpingectomy increased threefold 
(from 22% to 60%) from 2007 to 2017 [55]. Corresponding 
data from Korea are unavailable.
Concerns regarding potential disadvantages 
of prophylactic salpingectomy
During salpingectomy, the fallopian tubes are typically re-
sected from the fimbrial end to the uterine cornu. In particu-
lar, the fimbrial end should be completely removed, as most 
STICs originate from the fimbrial end. Some authors suggest-
ed that salpingectomy does not cause functional damage to 
the ovary, because the ovarian blood supply is guaranteed 
both by infundibulopelvic vessels and the ovarian branch of 
the uterine artery [56]. However, the potential disadvantages 
to the ovarian reserve owing to diminished ovarian arterial 
blood flow after salpingectomy are still debatable. Therefore, 
resection is performed at the posterior margin of the fallo-
pian tubes, while conserving the mesosalpinx (Figs. 2 and 3).
1.  Prophylactic salpingectomy during open and 
laparoscopic hysterectomy
It was reported that compared to hysterectomy alone, sal-
pingectomy along with hysterectomy did adversely affect 
ovarian reserve. Morelli et al. [57] retrospectively compared 
the data of 79 women who underwent laparoscopic hys-
terectomy along with bilateral salpingectomy with those 
of 79 women who underwent laparoscopic hysterectomy 
alone. They reported that there was no significant differ-
ence between the 2 groups in the postoperative changes of 
anti-Müllerian hormone (AMH, P=0.35), follicle-stimulating 
hormone (FSH, P=0.15), antral follicle count (AFC, P=0.09), 
mean ovarian diameters (P=0.57), and peak systolic veloc-
ity (PSV, P=0.61). Similarly, the ovarian reserve-related fac-
tors including AMH were compared between women who 
underwent hysterectomy alone and those who underwent 
hysterectomy along with salpingectomy in almost all previ-
ous studies, and results consistent to those observed in the 
study by Morelli et al. [57] were reported [58-61]. However, 
Fig. 3. Schematic representation of salpingectomy.
Fig. 2. Laparoscopic salpingectomy. Fallopian tubes are resected from the fimbrial end to the uterine cornu. Careful resection is performed 
at the posterior margin of the fallopian tubes, while conserving the mesosalpinx.
A  B  C
D  E  F
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limited evidence in terms of the short-term outcomes after 
salpingectomy exists, and no long-term outcome (such as an 
effect on actual menopausal timing) of this procedure has 
been reported. Many authors also showed that compared 
to hysterectomy alone, salpingectomy along with hysterec-
tomy did not impair surgical outcomes including operation 
time, hemoglobin decrement, return to normal activity, and 
operation-related complications. Only Van Lieshout et al. [61] 
reported a significantly longer operation time in the group 
of women who underwent salpingectomy plus hysterectomy 
than in the group of women who underwent hysterectomy 
alone (2.0 [1.3–2.4] vs. 1.5 [1.3–2.1] hours, P=0.02).
Using a Markov Monte Carlo simulation model, Kwon 
et al. [62] proved that although salpingectomy along with 
hysterectomy was socioeconomically less expensive than hys-
terectomy alone ($11,044.32±1.56 vs. $11,206.52±29.81), 
it was more effective in terms of increased life expectancy 
(21.12±0.02 vs. 21.10±0.03 years). These results indicate 
that salpingectomy could be a life-saving procedure, in that 
it could decrease the risk of ovarian cancer and unplanned 
pregnancies in high-risk women. A recently published study 
with cost-effectiveness analysis showed that prophylactic 
salpingectomy along with laparoscopic hysterectomy would 
save nearly $24 million per year and could confer an addi-
tional 500 quality-adjusted life years (QALYs) [63].
2.  Prophylactic salpingectomy during vaginal 
hysterectomy
When technically feasible, vaginal hysterectomy remains the 
minimally invasive surgical option of choice for benign dis-
ease. However, salpingectomy during vaginal hysterectomy 
requires a different technical skill, and it is associated with a 
Fig. 4. Salpingectomy during cesarean delivery. (A, B) The engorged vessels in the mesosalpinx and the broad ligament during pregnancy; 
(C) resection of the tubo-ovarian ligament and mesosalpinx as close as possible to the fallopian tube, with ligation of engorged tubal ves-
sels; and (D) resection of the fallopian tube at the uterine cornu.
A  B 
C  D
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modest increase in operation-related complications. There-
fore, a recent study demonstrated that in 16.5% of cases, 
salpingectomy is performed with vaginal hysterectomy, while 
in 55.8% of cases, salpingectomy is performed with hyster-
ectomy via other routes [64]. Unfortunately, there is a lack of 
evidence for prophylactic salpingectomy in clinical procedures 
other than open and laparoscopic hysterectomy. Cadish et 
al. [65] suggested that salpingectomy with vaginal hysterec-
tomy is a cost-effective strategy ($7,350.62 vs. $8,113.45) 
considering its cancer- preventive effect, although operation-
related complications minimally increase with this procedure, 
compared to those observed with vaginal hysterectomy alone 
(7.95% vs. 7.68%).
3. Prophylactic salpingectomy during cesarean delivery
Tubal ligation has been performed in women who desire 
permanent sterilization at the time of cesarean delivery. Al-
though there are limited data on prophylactic salpingectomy 
performed in pregnant women, evaluation of the feasibility 
and safety of this procedure in this setting is important in 
terms of prevention of ovarian/fallopian/peritoneal cancer. 
However, a careful surgical approach is required, because the 
increased vascular supply to the broad ligament and fallopian 
tubes during pregnancy can easily lead to vascular injury 
and blood loss (Fig. 4). Several randomized controlled trials 
showed that bilateral salpingectomy during cesarean delivery 
seems as safe as tubal ligation in terms of operation-related 
complications. Subramaniam et al. [66] enrolled women at 
35 weeks of gestation or greater who desired permanent 
sterilization at the time of cesarean delivery, and randomized 
a total of 80 women after skin incision to bilateral salpingec-
tomy or bilateral tubal ligation (n=40 per group). Bilateral sal-
pingectomy required 15 more minutes than cesarean delivery 
alone did (75.4±29.1 vs. 60.0±23.3 minutes, P=0.004). How-
ever, no sterilization-related complications were observed 
in any of the groups. Ganer Herman et al. [67] also showed 
longer operation time in women who underwent bilateral 
salpingectomy than in those who did not undergo salpingec-
tomy (66.0±20.5 vs. 52.0±15.8 minutes, P=0.01); however, 
the rates of operation-related complications and hemoglobin 
decrement were similar in the 2 groups. The authors stated 
that salpingectomy seems to be a safer alternative to tubal 
ligation in women who desire permanent sterilization, during 
a planned cesarean delivery.
Conclusion
Current evidences support that the fallopian tube plays a major 
role in the carcinogenesis of ovarian/fallopian/peritoneal cancer, 
and that bilateral salpingectomy seems to be an effective risk-
reducing option. With the increasing adoption of prophylactic 
salpingectomy, the rate of ovarian/fallopian/peritoneal cancer in 
the general population is expected to gradually decrease over 
time. Women not at a high risk for EOC who have completed 
their families should be carefully considered for prophylactic sal-
pingectomy at the time of their scheduled gynecologic surgery. 
Further prospective trials for prophylactic salpingectomy in vari-
ous clinical settings, including non-gynecologic surgery, are war-
ranted.
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